Diagnostics developer Sherlock Biosciences has advanced its molecular diagnostic capabilities, which can now produce faster results on low-cost devices. The startup will use its Series B round of funding to expand the reach of its technology, potentially placing it directly in the hands of consumers around the world.
The Food and Drug Administration had previously granted an emergency use authorization for Abbott's ID NOW point-of-care test, a decision for which the agency came under fire amid reports of the test delivering inaccurate results.
Join us on February 26 at 3 pm ET, and we’ll dive into the key areas where practices are losing time and money and provide solutions to overcome them.
The Cambridge, Massachusetts-based company, co-founded by CRISPR pioneer Feng Zhang, said Thursday that it had received an emergency use authorization for its SARS-CoV-2 test, which works by programming a CRISPR molecule to pick up the virus' genetic signature.
The company aims to develop faster, lower-cost diagnostics using the gene-editing technology that could be used in oncology, infectious diseases, low-resource settings and other areas.